{"id":"https://openalex.org/W73364476","doi":null,"title":"Mitigation of Endothelial Dysfunction by Saxagliptin in High-Fat Diet/Streptozotocin-Induced Diabetic Rats","display_name":"Mitigation of Endothelial Dysfunction by Saxagliptin in High-Fat Diet/Streptozotocin-Induced Diabetic Rats","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W73364476","mag":"73364476"},"language":"en","primary_location":{"id":"mag:73364476","doi":null,"is_oa":false,"landing_page_url":"http://www.sapub.org/global/showpaperpdf.aspx?doi=10.5923/j.medicine.20140301.02","pdf_url":null,"source":{"id":"https://openalex.org/S4210193668","display_name":"Basic Sciences of Medicine","issn_l":"2167-7344","issn":["2167-7344","2167-7352"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Basic Sciences of Medicine","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077109998","display_name":"Amany N. Ibrahim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amany N. Ibrahim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037895428","display_name":"Amal Mohamad Husein Mackawy","orcid":"https://orcid.org/0000-0002-6191-8267","observed_orcids":["https://orcid.org/0000-0002-6191-8267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amal Mh Mackawy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080140729","display_name":"Ola A. Megahed","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ola A. Megahed","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.00505577,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"3","issue":"1","first_page":"8","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5795999765396118,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.5795999765396118,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10155","display_name":"Nitric Oxide and Endothelin Effects","score":0.3747999966144562,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.010499999858438969,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/endothelial-dysfunction","display_name":"endothelial dysfunction","score":0.9639999866485596},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9470000267028809},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/high-fat-diet","display_name":"high-fat diet","score":0.8349999785423279},{"id":"https://openalex.org/keywords/streptozotocin-induced-diabetes","display_name":"streptozotocin-induced diabetes","score":0.9929999709129333},{"id":"https://openalex.org/keywords/nitric-oxide-bioavailability","display_name":"nitric oxide bioavailability","score":0.8399999737739563},{"id":"https://openalex.org/keywords/soluble-icam-1","display_name":"soluble ICAM-1","score":0.9399999976158142},{"id":"https://openalex.org/keywords/oxidative-stress","display_name":"oxidative stress","score":0.8389999866485596},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.6869999766349792},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.6930000185966492},{"id":"https://openalex.org/keywords/glucose-tolerance","display_name":"glucose tolerance","score":0.7900000214576721},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.6639999747276306},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.7289999723434448},{"id":"https://openalex.org/keywords/anti-inflammatory-activity","display_name":"anti-inflammatory activity","score":0.6949999928474426},{"id":"https://openalex.org/keywords/antihypertensive-effect","display_name":"antihypertensive effect","score":0.7279999852180481},{"id":"https://openalex.org/keywords/vascular-function","display_name":"vascular function","score":0.5709999799728394},{"id":"https://openalex.org/keywords/diabetic-rats","display_name":"diabetic rats","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8020017147064209},{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.7915516495704651},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7798694372177124},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.764057457447052},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.6590261459350586},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6239932775497437},{"id":"https://openalex.org/C2779280383","wikidata":"https://www.wikidata.org/wiki/Q257331","display_name":"Streptozotocin","level":3,"score":0.5778427124023438},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.5586580634117126},{"id":"https://openalex.org/C2780972559","wikidata":"https://www.wikidata.org/wiki/Q550061","display_name":"Endothelial dysfunction","level":2,"score":0.5352941155433655},{"id":"https://openalex.org/C2780609358","wikidata":"https://www.wikidata.org/wiki/Q2087205","display_name":"Impaired glucose tolerance","level":4,"score":0.41461181640625},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.3800601363182068},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.1591966152191162}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:73364476","doi":null,"is_oa":false,"landing_page_url":"http://www.sapub.org/global/showpaperpdf.aspx?doi=10.5923/j.medicine.20140301.02","pdf_url":null,"source":{"id":"https://openalex.org/S4210193668","display_name":"Basic Sciences of Medicine","issn_l":"2167-7344","issn":["2167-7344","2167-7352"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Basic Sciences of Medicine","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W191621842","https://openalex.org/W1493933897","https://openalex.org/W1607729794","https://openalex.org/W1842179070","https://openalex.org/W1928175618","https://openalex.org/W1966777419","https://openalex.org/W1971713336","https://openalex.org/W1972919038","https://openalex.org/W1973976170","https://openalex.org/W1974180544","https://openalex.org/W1980338958","https://openalex.org/W1981268963","https://openalex.org/W1983066944","https://openalex.org/W1991641597","https://openalex.org/W1998205437","https://openalex.org/W2000976083","https://openalex.org/W2007880055","https://openalex.org/W2011238752","https://openalex.org/W2011801069","https://openalex.org/W2015169646","https://openalex.org/W2028695980","https://openalex.org/W2028707869","https://openalex.org/W2032322539","https://openalex.org/W2045603155","https://openalex.org/W2053703172","https://openalex.org/W2056982572","https://openalex.org/W2064410761","https://openalex.org/W2064653291","https://openalex.org/W2065501573","https://openalex.org/W2072935519","https://openalex.org/W2078128383","https://openalex.org/W2087638953","https://openalex.org/W2096127054","https://openalex.org/W2109989702","https://openalex.org/W2113169712","https://openalex.org/W2118609667","https://openalex.org/W2121420099","https://openalex.org/W2129730863","https://openalex.org/W2138266804","https://openalex.org/W2138451589","https://openalex.org/W2142182024","https://openalex.org/W2146603936","https://openalex.org/W2147071181","https://openalex.org/W2151713210","https://openalex.org/W2158498099","https://openalex.org/W2165472969","https://openalex.org/W2166494634","https://openalex.org/W2168397692","https://openalex.org/W2169562373","https://openalex.org/W2324841714"],"related_works":["https://openalex.org/W2958502228","https://openalex.org/W2606362537","https://openalex.org/W2625417023","https://openalex.org/W2064653291","https://openalex.org/W3123027842","https://openalex.org/W2178461457","https://openalex.org/W2345101418","https://openalex.org/W2626618613","https://openalex.org/W2126328471","https://openalex.org/W7097215097"],"abstract_inverted_index":{"Background":[0],"and":[1,57,87,99,151,166,180,207,211,227,231],"Aim":[2],"Saxagliptin":[3,59,215,235],"is":[4,22,36],"a":[5,23,133,314,334],"dipeptidyl":[6],"peptidase-4":[7],"(DPP-4)":[8],"inhibitor":[9],"that":[10,49],"reduces":[11,294],"postprandial":[12],"plasma":[13],"glucose":[14,91,165,167,204,221,224],"associated":[15,37],"with":[16,38,132,256,326,341],"type":[17,94,338],"2":[18,95,126,339,352],"diabetes":[19,32,340],"mellitus.":[20,33],"It":[21],"novel":[24],"class":[25],"of":[26,31,41,55,79,143,191,264,271,274,278,287,310,321],"drugs":[27],"for":[28,122,137,160,337],"the":[29,53,76,177,192,265,269,279,295,301],"treatment":[30,216],"Diabetes":[34],"mellitus":[35],"an":[39,46,308],"induction":[40],"vascular":[42,212,296,303,324],"endothelial":[43,62,83,311,342],"dysfunction":[44,63],"(VED),":[45],"initial":[47],"event":[48],"could":[50],"lead":[51],"to":[52,74],"pathogenesis":[54],"atherosclerosis":[56],"hypertension.":[58],"effects":[60,320,329],"on":[61,81,323],"function":[64,312,325],"have":[65],"not":[66],"been":[67],"fully":[68],"elucidated.":[69],"This":[70],"study":[71,267],"was":[72,246],"designed":[73],"assess":[75],"possible":[77],"effect":[78],"saxagliptin":[80,157,275,322],"impaired":[82],"function,":[84],"oxidative":[85,213,297],"stress,":[86],"inflammation":[88],"beyond":[89],"blood":[90,164,170,209,220,230,233],"control":[92,115],"in":[93,176,189,251,307,313],"diabetic":[96,154,199,252,257,315],"rats.":[97],"Material":[98],"Methods":[100],"adult":[101],"male":[102],"Wistar":[103],"rats":[104,117,129,155,200,254],"were":[105,118,130,187],"randomly":[106],"divided":[107],"into":[108],"3":[109],"equal":[110],"groups.":[111,194],"Group":[112],"1,":[113],"Normal":[114],"group;":[116],"fed":[119,131,198],"normal":[120],"diet":[121,136,356],"16":[123],"weeks;":[124],"group":[125,152],"(diabetic":[127],"group),":[128],"high":[134,196],"fat":[135,197],"8":[138,161],"weeks":[139],"followed":[140],"by":[141,148,241,248,299],"administration":[142],"streptozotocin":[144],"(100mg/kg":[145],"body":[146],"weight)":[147],"intraperitoneal":[149],"injection":[150],"3,":[153],"received":[156],"(10mg/kg/day,":[158],"orally)":[159],"weeks.":[162],"Fasting":[163],"tolerance":[168,225],"test,":[169],"pressure,":[171,210],"nitric":[172],"oxide":[173],"(NO)":[174],"bioavailability":[175],"aortic":[178,244],"tissue":[179],"soluble":[181],"intracellular":[182],"adhesion":[183],"molecule":[184],"-1":[185],"(sICAM-1)":[186],"determined":[188],"serum":[190,238],"different":[193],"Results:":[195],"showed":[201],"increased":[202,247],"fasting":[203,219],"levels,":[205,304],"systolic":[206,229],"diastolic":[208,232],"stress.":[214],"significantly":[217],"decreased":[218,228,237],"level,":[222],"improved":[223],"test":[226],"pressure.":[234],"also":[236],"sICAM-1":[239],"levels":[240],"37%":[242],"(p\u22640.05),":[243],"NO":[245,302],"22%":[249],"(p\u22640.05)":[250],"treated":[253,259],"compared":[255],"non":[258],"group.":[260],"Conclusion:":[261],"The":[262],"results":[263],"present":[266],"support":[268],"concept":[270],"anti-inflammatory":[272],"properties":[273],"through":[276],"inhibition":[277],"pro-inflammatory":[280],"mediator,":[281],"including":[282],"sICAM-1,":[283],"which":[284,305],"are":[285],"independent":[286],"its":[288,327],"glucose-lowering":[289],"properties.":[290],"In":[291],"addition,":[292],"it":[293,332],"stress":[298],"increasing":[300],"resulted":[306],"improvement":[309],"rat":[316],"model.":[317],"These":[318],"beneficial":[319],"hypotensive":[328],"might":[330],"serve":[331],"as":[333],"potential":[335],"therapy":[336],"dysfunction.":[343],"Keywords":[344],"Saxagliptin,":[345],"DPP-4":[346],"inhibitor,":[347],"Endothelial":[348],"cell":[349],"(EC),":[350],"Type":[351],"diabetes,":[353],"sICAM-1molecule,":[354],"High-fat":[355]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}